테라노스틱스 시장 분석 및 예측 : 유형별, 제품 유형별, 서비스별, 기술별, 구성요소별, 용도별, 최종 사용자별, 기기별, 프로세스별(-2035년)

Theranostics Market is anticipated to expand from $3.6 billion in 2024 to $11.8 billion by 2034, growing at a CAGR of approximately 12.6%. The Theranostics Market encompasses the integration of therapeutic and diagnostic capabilities within a single platform, enabling personalized treatment strategies. This innovative approach combines targeted therapies with diagnostic imaging or biomarkers to enhance treatment efficacy and monitor therapeutic responses. As precision medicine gains traction, theranostics is poised for significant growth, driven by advancements in molecular imaging, nanotechnology, and biomarker discovery. The market is further propelled by increasing cancer prevalence and the demand for tailored healthcare solutions, promising substantial opportunities for stakeholders in the pharmaceutical and diagnostic sectors.

The Theranostics Market is poised for substantial growth, primarily driven by the integration of diagnostics and therapeutics in personalized medicine. Radiopharmaceuticals lead the market, with radioisotopes and radiolabeled peptides being pivotal in enhancing targeted cancer treatment. The imaging segment, comprising PET and SPECT technologies, follows closely, underscoring their importance in precise disease diagnosis. The oncology sub-segment is the top performer, driven by the rising prevalence of cancer and the need for targeted therapies. Cardiovascular theranostics, as the second highest performing sub-segment, is gaining momentum due to advancements in imaging agents for heart disease. Increasing collaboration between pharmaceutical companies and diagnostic firms is accelerating innovation in this field. Additionally, the integration of artificial intelligence in imaging and diagnostics is enhancing the accuracy and efficiency of theranostic solutions. The demand for minimally invasive procedures is further propelling market growth, as patients and healthcare providers seek safer and more effective treatment options.

Market Snapshot:

The Theranostics market is witnessing a dynamic shift in market share, driven by innovative pricing strategies and a surge in new product launches. Key industry players are leveraging advanced technologies to offer competitive pricing, enhancing accessibility and adoption. The market is characterized by a continuous influx of novel products, reflecting a robust pipeline of developments aimed at meeting the growing demand for personalized medicine. This trend underscores the industry's commitment to integrating therapeutic and diagnostic capabilities, positioning itself at the forefront of precision healthcare. Competition benchmarking reveals a landscape marked by strategic alliances and mergers, enhancing competitive advantage. Regulatory influences are pivotal, with stringent guidelines shaping market entry and product development. The landscape is dominated by a few key players, yet emerging companies are making significant inroads, driven by innovation and strategic partnerships. Regulatory frameworks in North America and Europe are particularly influential, dictating market dynamics and fostering a competitive environment ripe for growth. The market's future is promising, with technological advancements and regulatory support paving the way for continued expansion.

Geographical Overview:

The theranostics market is witnessing notable expansion across various regions, each exhibiting unique growth dynamics. North America is at the forefront, driven by advanced healthcare infrastructure and significant investments in personalized medicine. The region's focus on integrating diagnostics and therapeutics enhances its market leadership. Europe follows closely, with strong regulatory support and a growing emphasis on precision medicine fostering a conducive environment for theranostics. Asia Pacific is rapidly emerging as a lucrative market, propelled by substantial investments in healthcare and technological advancements. Countries like China and India are spearheading growth, driven by increasing healthcare expenditures and a rising demand for personalized treatment solutions. Latin America and the Middle East & Africa are also showing promising growth potential. In Latin America, improving healthcare infrastructure and rising awareness of personalized medicine are key drivers. Meanwhile, the Middle East & Africa are recognizing the value of theranostics in addressing regional healthcare challenges and improving patient outcomes.

Key Trends and Drivers:

The theranostics market is experiencing robust growth, propelled by advancements in personalized medicine and targeted therapies. A key trend is the integration of diagnostic and therapeutic capabilities, which enhances treatment precision and efficacy. This approach is gaining traction as healthcare systems aim to provide more tailored patient care. Increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, is a significant driver. These conditions necessitate innovative treatment solutions, further fueling theranostics adoption. Additionally, advancements in imaging technologies are enhancing diagnostic accuracy, enabling early detection and intervention. The rise of companion diagnostics is another notable trend, supporting the development of personalized treatment regimens. Regulatory bodies are increasingly approving theranostic products, reflecting growing confidence in their potential. Emerging markets present lucrative opportunities as healthcare infrastructure improves and demand for advanced treatments rises. Companies investing in research and development are poised to capitalize on these expanding opportunities, positioning themselves as leaders in the evolving theranostics landscape.

Restraints and Challenges:

The Theranostics Market encounters several notable restraints and challenges. A primary challenge is the substantial cost associated with integrating diagnostic and therapeutic technologies, which imposes financial burdens on healthcare providers and patients alike. This financial barrier limits accessibility and adoption, particularly in emerging markets. Regulatory complexities also pose significant challenges. Navigating the intricate approval processes for theranostic products can delay market entry and increase development costs. Moreover, the lack of standardized regulatory frameworks across different regions further complicates global market expansion. Another challenge is the limited awareness and understanding of theranostics among healthcare professionals. This knowledge gap can impede the effective implementation of these technologies in clinical settings, restricting their potential benefits. Additionally, the rapid pace of technological advancements in the field requires continuous investment in research and development. This necessity places pressure on companies to innovate while managing financial sustainability. Lastly, data privacy concerns related to patient information in theranostic applications present a significant hurdle. Ensuring robust data protection measures is crucial to gaining patient trust and regulatory compliance.

Key Players:

Advanced Accelerator Applications, Theragnostics, Lantheus Holdings, NanoMab Technology, Radiomedix, Telix Pharmaceuticals, Blue Earth Diagnostics, Isotopia Molecular Imaging, Sofie Biosciences, Endocyte, Navidea Biopharmaceuticals, Cyclopharm, ImaginAb, OncoNano Medicine, Cerveau Technologies

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Component
• 2.6 Key Market Highlights by Application
• 2.7 Key Market Highlights by End User
• 2.8 Key Market Highlights by Device
• 2.9 Key Market Highlights by Process

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Imaging Agents
  • 4.1.2 Therapeutic Agents
  • 4.1.3 Radioisotopes
  • 4.1.4 Biomarkers
  • 4.1.5 Nanoparticles
  • 4.1.6 Small Molecules
  • 4.1.7 Antibodies
  • 4.1.8 Peptides
  • 4.1.9 Gene Therapy
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Kits
  • 4.2.2 Reagents
  • 4.2.3 Instruments
  • 4.2.4 Software
  • 4.2.5 Consumables
  • 4.2.6 Assay Systems
  • 4.2.7 Diagnostic Devices
  • 4.2.8 Therapeutic Devices
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consultation
  • 4.3.2 Maintenance
  • 4.3.3 Installation
  • 4.3.4 Training
  • 4.3.5 Data Analysis
  • 4.3.6 Remote Monitoring
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 PCR
  • 4.4.2 NGS
  • 4.4.3 Immunoassays
  • 4.4.4 Mass Spectrometry
  • 4.4.5 Microarrays
  • 4.4.6 Flow Cytometry
  • 4.4.7 Liquid Biopsies
• 4.5 Market Size & Forecast by Component (2020-2035)
  • 4.5.1 Hardware
  • 4.5.2 Software
  • 4.5.3 Services
• 4.6 Market Size & Forecast by Application (2020-2035)
  • 4.6.1 Oncology
  • 4.6.2 Neurology
  • 4.6.3 Cardiology
  • 4.6.4 Infectious Diseases
  • 4.6.5 Endocrinology
  • 4.6.6 Gastroenterology
  • 4.6.7 Respiratory
• 4.7 Market Size & Forecast by End User (2020-2035)
  • 4.7.1 Hospitals
  • 4.7.2 Diagnostic Laboratories
  • 4.7.3 Research Institutes
  • 4.7.4 Pharmaceutical Companies
  • 4.7.5 Biotechnology Companies
  • 4.7.6 Academic Institutions
• 4.8 Market Size & Forecast by Device (2020-2035)
  • 4.8.1 PET Scanners
  • 4.8.2 MRI Scanners
  • 4.8.3 CT Scanners
  • 4.8.4 Ultrasound Devices
  • 4.8.5 Gamma Cameras
• 4.9 Market Size & Forecast by Process (2020-2035)
  • 4.9.1 In Vivo
  • 4.9.2 In Vitro

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Component
    • 5.2.1.6 Application
    • 5.2.1.7 End User
    • 5.2.1.8 Device
    • 5.2.1.9 Process
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Component
    • 5.2.2.6 Application
    • 5.2.2.7 End User
    • 5.2.2.8 Device
    • 5.2.2.9 Process
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Component
    • 5.2.3.6 Application
    • 5.2.3.7 End User
    • 5.2.3.8 Device
    • 5.2.3.9 Process
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Component
    • 5.3.1.6 Application
    • 5.3.1.7 End User
    • 5.3.1.8 Device
    • 5.3.1.9 Process
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Component
    • 5.3.2.6 Application
    • 5.3.2.7 End User
    • 5.3.2.8 Device
    • 5.3.2.9 Process
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Component
    • 5.3.3.6 Application
    • 5.3.3.7 End User
    • 5.3.3.8 Device
    • 5.3.3.9 Process
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Component
    • 5.4.1.6 Application
    • 5.4.1.7 End User
    • 5.4.1.8 Device
    • 5.4.1.9 Process
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Component
    • 5.4.2.6 Application
    • 5.4.2.7 End User
    • 5.4.2.8 Device
    • 5.4.2.9 Process
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Component
    • 5.4.3.6 Application
    • 5.4.3.7 End User
    • 5.4.3.8 Device
    • 5.4.3.9 Process
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Component
    • 5.4.4.6 Application
    • 5.4.4.7 End User
    • 5.4.4.8 Device
    • 5.4.4.9 Process
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Component
    • 5.4.5.6 Application
    • 5.4.5.7 End User
    • 5.4.5.8 Device
    • 5.4.5.9 Process
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Component
    • 5.4.6.6 Application
    • 5.4.6.7 End User
    • 5.4.6.8 Device
    • 5.4.6.9 Process
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Component
    • 5.4.7.6 Application
    • 5.4.7.7 End User
    • 5.4.7.8 Device
    • 5.4.7.9 Process
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Component
    • 5.5.1.6 Application
    • 5.5.1.7 End User
    • 5.5.1.8 Device
    • 5.5.1.9 Process
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Component
    • 5.5.2.6 Application
    • 5.5.2.7 End User
    • 5.5.2.8 Device
    • 5.5.2.9 Process
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Component
    • 5.5.3.6 Application
    • 5.5.3.7 End User
    • 5.5.3.8 Device
    • 5.5.3.9 Process
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Component
    • 5.5.4.6 Application
    • 5.5.4.7 End User
    • 5.5.4.8 Device
    • 5.5.4.9 Process
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Component
    • 5.5.5.6 Application
    • 5.5.5.7 End User
    • 5.5.5.8 Device
    • 5.5.5.9 Process
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Component
    • 5.5.6.6 Application
    • 5.5.6.7 End User
    • 5.5.6.8 Device
    • 5.5.6.9 Process
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Component
    • 5.6.1.6 Application
    • 5.6.1.7 End User
    • 5.6.1.8 Device
    • 5.6.1.9 Process
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Component
    • 5.6.2.6 Application
    • 5.6.2.7 End User
    • 5.6.2.8 Device
    • 5.6.2.9 Process
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Component
    • 5.6.3.6 Application
    • 5.6.3.7 End User
    • 5.6.3.8 Device
    • 5.6.3.9 Process
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Component
    • 5.6.4.6 Application
    • 5.6.4.7 End User
    • 5.6.4.8 Device
    • 5.6.4.9 Process
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Component
    • 5.6.5.6 Application
    • 5.6.5.7 End User
    • 5.6.5.8 Device
    • 5.6.5.9 Process

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Advanced Accelerator Applications
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Theragnostics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Lantheus Holdings
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 NanoMab Technology
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Radiomedix
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Telix Pharmaceuticals
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Blue Earth Diagnostics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Isotopia Molecular Imaging
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Sofie Biosciences
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Endocyte
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Navidea Biopharmaceuticals
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Cyclopharm
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 ImaginAb
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 OncoNano Medicine
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Cerveau Technologies
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us